Literature DB >> 3190991

The pharmacokinetics and pharmacodynamics of quinidine and 3-hydroxyquinidine.

R A Wooding-Scott1, J Smalley, J Visco, R L Slaughter.   

Abstract

1. The pharmacokinetics and pharmacodynamics of quinidine and 3-hydroxyquinidine based upon measurements of total and unbound serum concentrations were determined after a single dose (400 mg) and at steady state (200 mg every 6 h). 2. The oral clearance (7.6 +/- 1.9 vs 4.8 +/- 2.0 ml min-1 kg-1; P less than 0.05) and renal clearance (1.2 +/- 0.3 vs 0.63 +/- 0.25 ml min-1 kg-1; P less than 0.005) or quinidine were lower during steady state than after the single dose. 3. The area under the serum concentration vs time curve (AUC) of 3-hydroxyquinidine was greater at steady state than after the single dose (2.0 +/- 0.7 vs 3.0 +/- 0.6 mg l-1 h; P less than 0.05) and its renal clearance was less (3.0 +/- 1.1 vs 1.54 +/- 0.38 ml min-1 kg-1; P less than 0.05). 4. The slope of the relationship between quinidine concentration and change in QTc interval was greater at steady state (40.1 +/- 21.7 vs 72.2 +/- 41.7 ms/(mg l-1); P less than 0.05).

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3190991      PMCID: PMC1386563          DOI: 10.1111/j.1365-2125.1988.tb03400.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  15 in total

1.  Quinidine plasma concentration and exertional arrhythmia.

Authors:  G O Gey; R H Levy; G Pettet; L Fisher
Journal:  Am Heart J       Date:  1975-07       Impact factor: 4.749

2.  Pharmacokinetics of quinidine related to plasma protein binding in man.

Authors:  D Fremstad; O G Nilsen; L Storstein; J Amlie; S Jacobsen
Journal:  Eur J Clin Pharmacol       Date:  1979-04-17       Impact factor: 2.953

3.  Specific determination of quinidine and metabolites in biological fluids by reversed-phase high-performance liquid chromatography.

Authors:  R Leroyer; C Jarreau; M Pays
Journal:  J Chromatogr       Date:  1982-03-12

4.  Single and multiple dose pharmacokinetics of oral quinidine sulfate and gluconate.

Authors:  H R Ochs; D J Greenblatt; E Woo; K Franke; H J Pfeifer; T W Smith
Journal:  Am J Cardiol       Date:  1978-04       Impact factor: 2.778

5.  The effect of quinidine and its metabolites on the electrocardiogram and systolic time intervals: concentration--effect relationships.

Authors:  N H Holford; P E Coates; T W Guentert; S Riegelman; L B Sheiner
Journal:  Br J Clin Pharmacol       Date:  1981-02       Impact factor: 4.335

6.  Quinidine therapy in hospitalized patients with ventricular arrhythmias.

Authors:  N H Carliner; W G Crouthamel; M L Fisher; M A Mugmon; D L Vassar; P K Narang; G D Plotnick
Journal:  Am Heart J       Date:  1979-12       Impact factor: 4.749

7.  Steady-state serum levels of quinidine and active metabolites in cardiac patients with varying degrees of renal function.

Authors:  D E Drayer; D T Lowenthal; K M Restivo; A Schwartz; C E Cook; M M Reidenberg
Journal:  Clin Pharmacol Ther       Date:  1978-07       Impact factor: 6.875

8.  Total and unbound concentrations of quinidine and 3-hydroxyquinidine at steady state.

Authors:  R A Wooding-Scott; J Visco; R L Slaughter
Journal:  Am Heart J       Date:  1987-02       Impact factor: 4.749

9.  Assessment of quinidine gluconate for nonlinear kinetics following chronic dosing.

Authors:  J Russo; M E Russo; R A Smith; L K Pershing
Journal:  J Clin Pharmacol       Date:  1982 May-Jun       Impact factor: 3.126

10.  Quinidine pharmacokinetics in man: choice of a disposition model and absolute bioavailability studies.

Authors:  T W Guentert; N H Holford; P E Coates; R A Upton; S Riegelman
Journal:  J Pharmacokinet Biopharm       Date:  1979-08
View more
  3 in total

1.  Multi-functional scaling methodology for translational pharmacokinetic and pharmacodynamic applications using integrated microphysiological systems (MPS).

Authors:  Christian Maass; Cynthia L Stokes; Linda G Griffith; Murat Cirit
Journal:  Integr Biol (Camb)       Date:  2017-04-18       Impact factor: 2.192

Review 2.  Pharmacokinetic justification of antiprotozoal therapy. A US perspective.

Authors:  J D Berman; L Fleckenstein
Journal:  Clin Pharmacokinet       Date:  1991-12       Impact factor: 6.447

3.  P-Glycoprotein and Breast Cancer Resistance Protein Transporter Inhibition by Cyclosporine and Quinidine on the Pharmacokinetics of Oral Rimegepant in Healthy Subjects.

Authors:  Rajinder Bhardwaj; Julie L Collins; Joseph Stringfellow; Jennifer Madonia; Matt S Anderson; Jeri-Anne Finley; David A Stock; Vladimir Coric; Robert Croop; Richard Bertz
Journal:  Clin Pharmacol Drug Dev       Date:  2022-03-19
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.